Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT02172430 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2000
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation in patients with COPD using oxitropium bromide (Tersigan) as a comparator. Secondarily, the long-term efficacy of Ba 679 BR is also investigated

NCT ID: NCT02172404 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: October 2000
Phase: Phase 3
Study type: Interventional

Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI

NCT ID: NCT02172391 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 2000
Phase: Phase 3
Study type: Interventional

Trial to investigate the acute and chronic effect of tiotropium therapy on airway diameter in COPD patients as measured by inspiratory capacity (IC).

NCT ID: NCT02172378 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Start date: May 2000
Phase: Phase 3
Study type: Interventional

Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.

NCT ID: NCT02172352 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

Start date: July 1998
Phase: Phase 2
Study type: Interventional

To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings

NCT ID: NCT02172300 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: June 1999
Phase: Phase 3
Study type: Interventional

Study to investigate whether tiotropium therapy can increase duration of steady-state exercise by decreasing dynamic and static lung hyperinflation in COPD patients.

NCT ID: NCT02172287 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD
Start date: February 1999
Phase: Phase 3
Study type: Interventional

To compare the long -term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo in patients with COPD. A secondary objective of this study was to compare the impact of tiotropium and salmeterol on humanistic and economic health outcomes, such as quality of life, patient preference and Health Resource Utilisation in this patient population.

NCT ID: NCT02171377 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Quadricipital Electrical Stimulation in COPD Patients Rehabilitation

Reha-Res
Start date: August 2010
Phase: N/A
Study type: Interventional

Quadricipital electrical stimulation added to respiratory rehabilitation in COPD patients. Quadricipital electrical stimulation (ES) in chronic obstructive pulmonary disease (COPD) patients has been demonstrated to improve both dyspnea and physical status. The aim of our study is to demonstrate that ES added to respiratory rehabilitation program induces a greater improvement on exercise tolerance in such patients. Design : 160 patients with severe COPD will be randomly assigned to 2 groups : either rehabilitation program (group 1), either ES and rehabilitation program (group 2). In both groups, rehabilitation program comprises endurance training, 18 - 24 sessions (6 - 8 weeks), health education, global muscular strengthening. In group 2, bilateral quadricipital electrical stimulation 30 min sessions is added 5 days / week. Subjects : COPD patients with FEV1 < 60% pred, FEV1/VC < 70%, and TLC > 80%, with dyspnea, in stable conditions, and 18 > BMI < 35 kg/m² . Intervention : 6 min walking distance, incremental exercise test data (aerobic capacity, work rate, ventilatory threshold), physical activity with activity monitor, health related quality of life will be determined before and after training. Abbreviations : FEV1 = forced expiratory volume in 1 sec; VC = vital capacity; TLC = total lung capacity; BMI = body mass index.

NCT ID: NCT02168049 Completed - Heart Diseases Clinical Trials

Heart and Lung Function Monitoring System

Start date: November 2014
Phase: N/A
Study type: Interventional

The investigator goal is to test a new device to see if it can provide continuous and simultaneous monitoring of heart and lung function.

NCT ID: NCT02168036 Terminated - Lung Cancer Clinical Trials

Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.

Start date: August 16, 2011
Phase: N/A
Study type: Observational

The purpose of this protocol is to obtain biologic materials from the mediastinal lymph nodes from patients with lung disease and mediastinal lymph node involvement in order to: (1) develop a better understanding of the cause and development of lung disorders involving the mediastinal lymph nodes; (2) identify biologic parameters that help diagnose and predict the behavior of human lung diseases; and (3) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs.